Press Releases.
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation
Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar
Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network
Volition Issues Business Review 2022
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update
Volition Announces Clinical Research Study with Oncovet
Volition to Participate in a Lung Cancer Screening Study in France